Donovan Quill, serves a dual appointment as the Chief Strategy Officer of Life Sciences for both Actum Pharma and AscellaHealth. As co-founder and previous CEO of Optime Care, Donovan developed a distinguished background in the life sciences industry, with a proven track record of success delivering over 40 branded pharmaceutical programs for specialty pharmaceutical and biotech manufacturers. Leveraging his extensive experience in rare diseases and profound industry knowledge, Donovan spearheads strategy and business development by serving as a strategic partner and solutions provider to pharmaceutical manufacturers, building custom commercialization programs that meet the needs of patients with complex medical conditions and rare diseases.
Donovan's multi-faceted career encompasses working with not-for-profit, advocacy organizations, event planning, customer service, sales and nonprofit management. Donovan entered the world of healthcare after a successful coaching career and teaching at the collegiate level. His personal mission was to help patients who suffer from an orphan disorder that has affected his entire family (Alpha-1 Antitrypsin Deficiency). Donovan became a patient advocate for Centric Health Resources and traveled the country raising awareness, improving detection and providing education to patients and healthcare providers.
It's not just about awareness but also a call to action for patients, families, employers, payers and policymakers to modernize the systems that shape access to care. It must focus on connecting innovation with the infrastructure that governs approval, coverage and affordability.
A patient-first approach offers a proactive, process-driven program that leverages telehealth consults which can effectively mitigate the transmission of infection, such as coronavirus, for these vulnerable individuals.
Across the nation, state-based health insurance exchanges are searching for ways to better serve their communities while making enrollment easier, more personal, and more accessible for everyone.